minzasolmin

Minzasolmin is an orally administered, small-molecule drug developed as a potential disease-modifying therapy for Parkinson’s disease. It acts as an α-synuclein aggregation inhibitor, targeting the early steps of the α-synuclein (ASYN) cascade by specifically inhibiting ASYN misfolding and oligomerization. This mechanism aims to reduce pathological protein aggregation implicated in Parkinson’s disease and related synucleinopathies such as dementia with Lewy bodies and multiple-system atrophy. Minzasolmin was discovered at Neuropore, later licensed to UCB, and subsequently co-developed with Novartis. Preclinical studies demonstrated that minzasolmin reduced α-synuclein pathology, neuroinflammation, and motor impairments in animal models. The drug readily crosses the blood–brain barrier and distributes well throughout brain tissue[2][4][5]. Despite promising preclinical results and initial clinical trials evaluating its efficacy in slowing progression of Parkinson's disease symptoms[6][7], development was discontinued after failing to meet primary endpoints in a large phase II trial[8].

Brand names

minzasolmin

Other names

minzasolminUCB0599UCB-0599UCB 0599NPT-200-11NPT200-11NPT 200-11